All News

#ACR21 #Abstr1425 Interim AURORA2 (Extension of original RCT to 2 years) showed #lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs. No unexpected safety signals @RheumNow https://t.co/aclJZNOGc5 https://t.co/ENl9SzMHN3

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How much PNL do you need with TCZ in GCA, to avoid early risks of visual loss? GiACTA: 26w. Can we do better? GUSTO: 3d pulse IVMP. Not enough. Is 8w the sweet spot?🤔 sustained remission off PNL at 52w: 20/27 no visual loss/ischaemia @MGHrheumatology #ACR21 ABST1413 @RheumNow https://t.co/IV9MorvTeW
David Liew drdavidliew ( View Tweet)
#Voclosporin still going strong in LTE in #lupus nephritis AURORA 2. No new safety signals, stable GFR. Cost may be problem! Abst#1425 #ACR21 #ACRBest @RheumNow https://t.co/biEptZbJoz
Janet Pope Janetbirdope ( View Tweet)
#ACR21 Abs#1426 - VEXAS! Predictors of mortality: ▶️p.MetVal41 genotype (HR 3.5) ▶️Absence of ear chondritis (HR 3.8) ▶️Transfusion dependence (HR 2.6) @Rheumnow https://t.co/m5bl9Ho163 https://t.co/LSNcF6EZHv

Links:

Eric Dein ericdeinmd ( View Tweet)
Abst1338 #acr21 @RheumNow BE ACTIVE Bimekizumab in 206 PsA: Over half of TNFi-n pts achieved ACR50 resolution of dactylitis (70.2% NRI; 100.0% OC) & enthesitis (60.7% NRI; 80.6% OC) PASI100 at Wks 48/152 63.3/58.7% Low serious infect, mild/moderate candida. 1 microscopic colitis https://t.co/CJXyywZYJd
Olga Petryna DrPetryna ( View Tweet)
Abstr 1044 Anastasiou & colleagues examined Rx of inappropriate medications in elderly patients with rheumatic disease (RD) - 40% RD patients received inappropriate meds - Elderly living in areas of low SES likely to receive opioid Rx #ACR21 @RheumNow #BeersCriteria https://t.co/fxBGVAtt1L
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR21 #Abstr1426 VEXAS is only recently described but a study in 83 patients showed importance of genotyping + clinical in predicting mortality: 💠p.Met41Val (OR: 2.6) 💠Transfusion dependent (4.5) 💠Ear chondritis protective (0.3) @RheumNow #ACRBest https://t.co/RQwONf2MJT https://t.co/VLWRGKWmQs

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The VEXAS story developing and becoming clearer... with high mortality genotype-phenotype linked genotype at risk for mortality (p.Met41Val) - smaller residual UBA1b expression - less RP - more fever wonderful from @maferradastrong #ACR21 ABST1426 @RheumNow @RP_Organization https://t.co/vELXprUrPh
David Liew drdavidliew ( View Tweet)
Voclosporin for lupus nephritis maintained reductions in proteinuria. No change in eGFR at 30 months of treatment (AURORA 2 study) Abs#1425 #ACR21 @RheumNow https://t.co/1y9oSVXzD8
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abs#1427- Statin Use in RA ⭐️# needed to treat: 42 pts all-cause mortality ⭐️NNT 102 pts CVD events ⭐️# needed to harm: 127 pts T2DM (mild ⬆️ risk) ▶️Statin use: mortality benefit better than gen pop, CVD&DM similar effects to gen pop @Rheumnow https://t.co/m5bl9Ho163 https://t.co/hijxbcVBzA

Links:

Eric Dein ericdeinmd ( View Tweet)
I've written more about these really useful data here for @RheumNow: https://t.co/3dQteFr9qZ #ACR21 @earlyarthritis @BykerkVivian https://t.co/7HufoWVtCK

Links:

David Liew drdavidliew ( View Tweet)

AURORA 2 (A2): SLE + LN AURORA 1: Adding Voclosporin to MMF + Steroids ⬆️complete renal response by 18% @ 52w A2: @ 30 months 💠Maintained mean GFR 💠Maintained reductions in proteinuria 💠Further safety/efficacy data to follow https://t.co/wSvQvueKi7 #ACR2021 Abst#1425 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Median survival for pts w/#VEXAS➡️10 years Predictors of mortality w/VEXAS: 👉p.MetVal mutation HR 3.5 (95%CI, 1.4-8.5) 👉transfusion dependency HR 2.59 (95%CI, 0.94-7.09) 👉⬇️risk w/ear chondritis HR 0.26 (95%CI,0.09-0.6) @marcelaferrada #ACR21 @rheumnow Abstr#1426 #ACRbest

TheDaoIndex KDAO2011 ( View Tweet)

Plenary on VEXAS - good over view of VEXAS and why important to Rheums #ACR21 Abstract# 1426 https://t.co/jx0mQNlfwK
Dr. John Cush RheumNow ( View Tweet)
SLE Panel: Learning about Lupus at #ACR21 Drs. Kathryn Dao ( @KDAO2011) , Janet Pope ( @Janetbirdope) Yuz Yusof ( @Yuz6Yusof) Bella Mehta ( @bella_mehta) and Pedro Castillo ( @_Castillo_Pedro) discuss lupus-related data presented Saturday. https://t.co/h0vPIwUeOz https://t.co/eJDtRKPdYT

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Pearl from Dr. @JKolfenbach "Sometimes, taking off the mask is worth it" during physical exam: ➡️Strawberry gums in GPA ➡️Drug-induced gingival hyperplasia ‣ i.e. cyclosporine, CCB ➡️Tongue necrosis in GCA ➡️Ovoidal palatal patch in TIF1gamma DM #ACR21 @RheumNow https://t.co/H98bTLLse6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Wonderful overview of myositis autoantibodies to reference from the Rheum Secrets & Pearls session by Dr. @JKolfenbach & Dr. John Stone at #ACR21 that can be accessed on-demand now! @RheumNow https://t.co/H6N02MzFSu
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr1423 Munroe & James developed a novel #Lupus Classification Risk Immune Index using either 9 or 32 soluble mediators from sera. This index could predict transition to meeting classification criteria (with or without autoantibodies) @RheumNow https://t.co/Kr9fWaoW1L https://t.co/8wkgrzeRnt

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Spanish study finds OP is more frequent in male PsA pts, assoc'd w/age independent of dz hx. Femoral OP more frequent in pts w/ axial involvement, HTN, heart ischemic disease & vitamin D deficiency. Abs 1325 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/A3v6ZHZnN8 https://t.co/2jfAOSuLtK

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
We @HSpecialSurgery previously demonstrated improved fetal mortality in #lupus in @AnnalsofIM Racial disparities persist ~61K #lupus pregnancies - 10 yr US national data #abst1034 at #ACR21 more reduction in Asians and Hispanics than African Americans @RheumNow https://t.co/KeO0FdMB7f
Bella Mehta bella_mehta ( View Tweet)
×